SEC Comment Letter 0000000000-24-002254 to Benitec Biopharma Inc. (BNTC)
Benitec Biopharma Inc.
Date: Feb. 28, 2024 · CIK: 0001808898 · Accession: 0000000000-24-002254
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-277310
Letter
United States securities and exchange commission logo February 28, 2024 Jerel Banks, M.D., Ph.D. Chief Executive Officer Benitec Biopharma Inc. 3940 Trust Way Hayward, CA 94545 Re:Benitec Biopharma Inc. Registration Statement on Form S-3 Filed February 23, 2024 File No. 333-277310 Dear Jerel Banks: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Louis Rambo, Esq.
Show Raw Text
United States securities and exchange commission logo
February 28, 2024
Jerel Banks, M.D., Ph.D.
Chief Executive Officer
Benitec Biopharma Inc.
3940 Trust Way
Hayward, CA 94545
Re:Benitec Biopharma Inc.
Registration Statement on Form S-3
Filed February 23, 2024
File No. 333-277310
Dear Jerel Banks:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Louis Rambo, Esq.